Press release
Vantage Vascular Selected for National RESORB Knee test Brooklyn NY and Fair Lawn NJ
Brooklyn, NY, United States, 10th Jul 2026 - Vantage Vascular, an outpatient vascular and interventional radiology practice serving patients across New York and New Jersey, has been selected as one of just over 10 leading U.S. clinical sites chosen to participate in the RESORB clinical test, a landmark national study evaluating a breakthrough, non-surgical treatment for knee osteoarthritis pain.
Being named a RESORB test site is not automatic. NEXTBIOMEDICAL, the study sponsor, specifically sought out practices with the clinical expertise, imaging capabilities, and patient-first infrastructure to effectively conduct a pivotal FDA test.
RESORB (Randomized Controlled Study Evaluating Genicular Artery Embolization Against Intra-Articular Corticosteroid Knee Injection for Osteoarthritic Knee Pain) is a pivotal, FDA-approved clinical test comparing genicular artery embolization (GAE) using an investigational device called Nexsphere F to a standard corticosteroid knee injection. The test is enrolling approximately 126 patients across more than 10 U.S. sites and is registered on ClinicalTrials.gov as NCT06872567.
Genicular artery embolization is a minimally invasive, outpatient procedure in which board-certified interventional radiologists use image guidance to deliver tiny particles into blood vessels feeding the inflamed tissues of the knee.
Nexsphere F is a novel, fast-resorbable microsphere technology. Unlike permanent embolic agents, Nexsphere F microspheres dissolve naturally within 2 to 6 hours after the procedure.
Term blockage of blood flow. The device has already received FDA Breakthrough Device Designation, CMS IDE Category B approval (meaning Medicare covers the procedure during the test), and CE-MDD certification in Europe, where it has been used in thousands of procedures with a strong safety record.
Why Being a Selected test Site Matters for Patients
Clinical test site selection for an FDA pivotal study is highly competitive. Sponsors identify practices based on physician expertise, procedural volume, imaging infrastructure, and the ability to safely manage research protocols.
For patients, what this means in practice is significant: Vantage Vascular is offering access to a treatment not yet available anywhere outside of these select test sites in the United States. If you have knee osteoarthritis pain that has persisted despite medications and conservative care for at least two months, and you are not currently planning knee surgery or replacement, you may be eligible to receive this FDA-monitored, cutting-edge procedure at no cost through the test.
The tests national Principal Investigator and Chief Medical Officer for NEXTBIOMEDICAL is Dr. Ziv J. Haskal, MD, Professor of Interventional Radiology at the University of Virginia. The clinical evidence behind Nexsphere F continues to grow: a published study in the Journal of Vascular and Interventional Radiology evaluating 155 patients treated with resorbable microspheres found a 67% average reduction in pain at 6 months, with no device-related serious adverse events.
Who May Be Eligible
The RESORB test is enrolling adults who:
o Have knee osteoarthritis pain that has not responded adequately to conservative treatments for at least 2 months
o Are not currently planning knee surgery or knee replacement
o Meet the study's eligibility criteria as reviewed by Vantage Vascular's clinical team
If enrolled, participants are randomly assigned to receive either GAE with Nexsphere F or a corticosteroid knee injection. Those initially assigned to the corticosteroid injection have the option to receive GAE after 180 days. The test runs approximately 12 to 18 months, and participation is always voluntary.
The test is FDA-IDE and IRB-approved (IRB approval at the protocol level: October 31, 2025). During the test, the procedure is covered under CMS IDE Category B, meaning Medicare-eligible patients may have coverage for test participation.
Schedule a Consultation at Vantage Vascular
If you or someone you know has been living with chronic knee pain, now is the time to explore whether you qualify. Vantage Vascular's team will evaluate your history, imaging, and treatment background to determine eligibility and walk you through every step of the process with the same compassionate, patient-first care the practice is known for.
Enrollment is currently open at Vantage Vascular's Brooklyn and New Jersey locations. Call or visit the practice online to schedule a consultation.
Brooklyn Flatlands Clinic: 2035 Ralph Ave, Suite B5, Brooklyn, NY 11234
Brooklyn Midwood Clinic: 603 Rugby Road, Suite 3, Brooklyn, NY 11230
New Jersey Fair Lawn Clinic: 15-01 Broadway, Suites 1-3, Fair Lawn, NJ 07410
NY: (718) 247-8794 | NJ: (201) 812-2929 | Monday-Friday: 8AM-6PM | vantagevascular.com
About Vantage Vascular
Vantage Vascular is an outpatient vascular and interventional radiology practice with locations in Brooklyn, New York and Fair Lawn, New Jersey. Led by Dr. Vishal K. Sinha, MD (Founder & President) and Dr. Christopher M. Harnain, MD, MBA, RPVI (Chief of Interventional Radiology & Founding Member), the practice's Ivy League-educated, board-certified interventional radiologists deliver world-class, minimally invasive treatments for joint pain, vascular conditions, women's health, and more -- all in a comfortable outpatient setting, with no hospital stays or prolonged recovery. Vantage Vascular is dedicated to advancing patient care through innovation, clinical excellence, and a deep commitment to the communities of New York and New Jersey.
About the RESORB test
RESORB is a randomized, open-label, FDA-IDE and IRB-approved pivotal clinical test evaluating genicular artery embolization with Nexsphere F against intra-articular corticosteroid knee injection for osteoarthritic knee pain. The study is registered on ClinicalTrials.gov as NCT06872567, with an estimated enrollment of 126 participants at more than 10 leading U.S. clinical sites. Nexsphere F has received FDA Breakthrough Device Designation, CMS IDE Category B approval, and CE-MDD certification in Europe.
Important Research Notice
Nexsphere F is an investigational device not yet approved or cleared by the FDA for commercial use in the United States. It is available only through the RESORB clinical test at authorized test sites. Participation is subject to eligibility criteria, informed consent, site availability, and investigator review. Individual results may vary. Medicare coverage under CMS IDE Category B applies to eligible participants during the test period; patients should confirm coverage with Vantage Vascular and their insurer.
Contact Details
Organization: Vantage Vascular
Contact Person: Vishal K. Sinha
Website: https://vantagevascular.com/
Email: Send Email [https://dashboard.kingnewswire.com/release-contact/46614]
Contact Number: +17182478794
Address: 2035 Ralph Ave Ste B
City: Brooklyn
State: NY
Country: United States
Release Id: 10072646614
The post Vantage Vascular Selected for National RESORB Knee test Brooklyn NY and Fair Lawn NJ appeared first on King Newswire. This content is provided by a third-party source. King Newswire is a press release distribution agency. We do not accept any responsibility or liability for the accuracy, content, images, videos, licences, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright concerns related to this article, please contact the company listed in the 'Media Contact' section above.
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. king Newswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact support@kingnewswire.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Vantage Vascular Selected for National RESORB Knee test Brooklyn NY and Fair Lawn NJ here
News-ID: 4573567 • Views: …
More Releases from King Newswire
Octopus Moving Reminds Boston Renters: Keep Trucks Off Storrow Drive and Get Per …
The Boston moving company is issuing a public advisory ahead of the city's busiest moving weekend, when low bridges and last-minute permits cause the most avoidable damage and fines.
United States, 9th Jul 2026 - Octopus Moving, a licensed and insured moving company based in Boston, today issued a public advisory for renters preparing to move on or around September 1, the date when much of the city changes homes at…
B&W Productions Marks 33 Years With New South African Event Planning Platform
B&W Productions, a South African event management and production company founded in 1993, has launched a new digital platform as it marks 33 years in business.
MEYERTON RANDVAAL, South Africa, July 8, 2026 -- B&W Productions, a South African event management and production company founded in 1993, has launched a new digital platform as it marks 33 years in business. The new website brings together company information, service pages and a…
Scientology Volunteer Ministers Continue Bringing Help and Hope to Venezuela Aft …
As the emergency moves from rescue to recovery, volunteers support families, rescue teams and local communities with supplies, logistics and practical assistance in Caracas, La Guaira and surrounding areas.
Brussels, Brussels, Belgium, 9th Jul 2026 -- In the aftermath of the powerful double earthquake that struck Venezuela on 24 June, Scientology Volunteer Ministers continue to stand with affected families and emergency teams as the country moves from the first days of…
Pump.fun Volume Bot Builds Volume, Holders and Comments as One Coherent Signal
United States, 9th Jul 2026 - Pump.fun Volume Bot builds volume, unique holders, native-language comments and favorites in proportion so a Solana launch reads as genuine interest to the Pump.fun trending feed, running non-custodially from the browser at a single flat all-in fee and handing the session off to Raydium automatically at graduation.
Pump.fun Volume Bot, available at www.pumpfunvolumebot.space, has opened general access to a Pump.fun Volume Bot that is built…
More Releases for Vascular
High Prevalence Of Vascular Diseases Drives Global Vascular Grafts Market: An Em …
The Vascular Grafts Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Vascular Grafts Market?
In recent years, there has been consistent growth in the size of the vascular grafts market. The market is projected to expand from $3.25 billion…
Vascular Disease Surge Fuels Anticipated Growth In The Vascular Embolization Mar …
The Vascular Embolization Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Vascular Embolization Market Size and Its Estimated Growth Rate?
The growth of the vascular embolization market has been robust in recent times, escalating from $3.15 billion in 2024 to an estimated…
Vascular Embolization Market - Empowering Vascular Wellness through Embolization
Newark, New Castle, USA: The "Vascular Embolization Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Vascular Embolization Market: https://www.growthplusreports.com/report/vascular-embolization-market/8433
This latest report researches the industry structure, sales, revenue,…
Large Bore Vascular Closure Devices Market Is Booming Worldwide | Abbott Vascula …
The Large Bore Vascular Closure Devices Market report provides the overall structure and business outlook of the global and regional industries. The study also involves the important Achievements of the market, Research & Development, new product launch, product responses, and regional growth of the leading competitors operating in the market on a global and local scale. This study provides information about the growth and revenue during the historic and forecasted…
Vascular Stent Market - Opportunities Outlook & Key Players 2025 | Vascular Conc …
Global Vascular Stent Market: Snapshot
The global market for vascular stents has been growing at a robust rate on account of the rising incidence of cardiovascular diseases across the globe. The healthcare industry has been witnessing an overbearing amount of patients who have suffered heart strokes or cardiac arrests. This has paved way for increased demand within the global market for vascular stents. These stents can be useful during angioplasty and…
Peripheral Vascular Device Market Size, Peripheral Vascular Device Market Share, …
Global Peripheral Vascular Device Market Size is observed to gain traction owing to the factors such as increasing research and development for developing several new product, and rising funding by the private organizations.
Request for Sample of This Research Report @ https://bit.ly/2xjOKpC
Top Key Player:-
Abbott Laboratories
Braun Melsungen AG
Boston Scientific Corporation
R. Brad, Inc.
Cardinal Health, Inc.
Medtronic plc.
Cook Medical, Inc.
Teruma Corporation
Jude Medical, Inc.
The Spectranetics Corporation
Volcano Corporation
Peripheral vascular disorder (PVD) is a blood circulation disorder…
